Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from CStone Pharmaceuticals ( (HK:2616) ) is now available.
CStone Pharmaceuticals announced that the National Medical Products Administration of China has approved the localized manufacturing of GAVRETO® (pralsetinib) for the Chinese market, starting in 2026. This transition from imported to locally manufactured products is expected to enhance supply chain flexibility and resilience, ensuring sustainable product access and strengthening GAVRETO®’s market position. The approval marks a significant milestone in CStone’s lifecycle management strategy, aiming to improve treatment accessibility for RET-positive patients in China.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015, is an innovation-driven biopharmaceutical company focusing on the research and development of anti-cancer therapies. The company has launched four innovative drugs and secured approvals for 16 new drug applications covering nine indications. CStone’s pipeline includes promising candidates such as antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines. The company is committed to addressing unmet medical needs in China and globally, supported by a management team with extensive experience across the drug development spectrum.
Average Trading Volume: 12,612,220
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.94B
For detailed information about 2616 stock, go to TipRanks’ Stock Analysis page.